Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 13

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 13
---
 Remaining Contractual Term (years)     Aggregate Intrinsic Value (in thousands)             $        $     Outstanding, March 31, 2025   934,923   3.52   8.26   24     Granted   391,530   2.15             Outstanding, June 30, 2025   1,326,453   3.12   8.58   594     Exercisable, June 30, 2025   674,890   3.81   7.96   219  
  The weighted-average grant date fair value of awards for options granted during the three months ended June 30, 2025 was $1.78. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:               Three months ended June 30, 2025      Three months ended June 30, 2024         Weighted-average      Weighted-average      Exercise price  $2.15   $2.96     Share price  $2.15   $2.96     Dividend    —      —      Risk-free interest   4.02%   4.43%    Estimated life (years)   5.74    5.81     Expected volatility   109.43%   114.37% 

  17
  

Compensation expense recognized under the 2024 Plan and the Prior Plan is summarized as follows:  
  
  Three months ended     

  June 30, 2025

  June 30, 2024

    $ 
    $ 

  Research and development expenses
  
   69 
   65 

  General and administrative expenses
  
   233 
   173 

   302 
   238 
 
  As of June 30, 2025, there was $710 of total unrecognized compensation cost, related to non-vested stock options, which is expected to be recognized over a remaining weighted-average vesting period of 1.42 years. 

   8. Loss per share

   The Company has generated a net